A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Launched by JUNO THERAPEUTICS, INC., A BRISTOL-MYERS SQUIBB COMPANY · Sep 24, 2024
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called QUINTESSENTIAL-2, is testing a new treatment called BMS-986393 to see how well it works compared to standard treatments for adults with relapsed or refractory multiple myeloma (a type of blood cancer). Specifically, the study focuses on patients whose disease has not responded to lenalidomide, a common medication for multiple myeloma. The trial is currently looking for participants aged 65 to 74 who have had at least one but no more than three previous treatments and have measurable signs of their disease.
If you or someone you know is eligible, participants can expect to receive either the new treatment or one of the standard therapies and will be closely monitored for how well the treatment works and any side effects. It's important to note that participants should not have certain serious conditions, such as active brain involvement from cancer, and should not need urgent treatment for rapidly worsening disease. This study aims to provide valuable information that could help improve future treatment options for patients with multiple myeloma.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- • Participants must have relapsed or refractory multiple myeloma (RRMM).
- • Participants must have received at least 1 but no greater than 3 prior multiple myeloma (MM) regimens which may include a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 monoclonal antibody and have prior exposure to lenalidomide.
- • Participants must have a documented diagnosis of MM as per International Myeloma Working Group Criteria.
- • Participants must have measurable disease during screening.
- • Participants must have adequate organ function.
- • Participants must have an Eastern Cooperative Oncology group performance status 0 or 1.
- • Exclusion Criteria
- • Participants must not have known active or history of central nervous system (CNS) involvement of Multiple Myeloma (MM).
- • Participants must not have solitary plasmacytomas or non-secretory myeloma without other evidence of measurable disease.
- • Participants must not need urgent treatment due to rapidly progressing MM.
- • Other protocol-defined Inclusion/Exclusion criteria apply.
About Juno Therapeutics, Inc., A Bristol Myers Squibb Company
Juno Therapeutics, Inc., a Bristol-Myers Squibb company, is a biopharmaceutical organization dedicated to advancing innovative cell therapies for the treatment of cancer. With a strong focus on harnessing the power of the immune system, Juno is at the forefront of developing cutting-edge therapies, including CAR T-cell and TCR therapies, aimed at addressing unmet medical needs in hematologic malignancies and solid tumors. As a leader in the field of immuno-oncology, Juno Therapeutics combines rigorous scientific research with a commitment to patient-centric solutions, striving to improve outcomes for patients battling cancer worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Philadelphia, Pennsylvania, United States
Adelaide, South Australia, Australia
Vancouver, British Columbia, Canada
Camperdown, New South Wales, Australia
Atlanta, Georgia, United States
Wuerzburg, , Germany
Fukuoka, , Japan
Yamagata, , Japan
Hamburg, , Germany
Kumamoto, , Japan
Hannover, Niedersachsen, Germany
Patras, , Greece
Leipzig, Sachsen, Germany
Melbourne, Victoria, Australia
Osaka, , Japan
Tokyo, , Japan
Manchester, , United Kingdom
Nagoya, Aichi, Japan
Okayama, , Japan
Utrecht, , Netherlands
Rozzano, Milano, Italy
Pamplona, Navarra, Spain
Buenos Aires, , Argentina
Pierre Bénite, , France
Huddinge, , Sweden
Tel Aviv, , Israel
Gent, Oost Vlaanderen, Belgium
Clayton, Victoria, Australia
Jerusalem, Yerushalayim, Israel
Praha 2, , Czechia
Porto, , Portugal
Athens, , Greece
Vienna, , Austria
Linz, , Austria
Bucuresti, , Romania
Linz, Oberösterreich, Austria
Copenhagen, Hovedstaden, Denmark
St.Gallen, Sankt Gallen, Switzerland
Salamanca, , Spain
Aarhus, Midtjylland, Denmark
Ramat Gan, Hamerkaz, Israel
Odense, Syddanmark, Denmark
Brno, Brno Město, Czechia
Oslo, , Norway
Gdańsk, Pomorskie, Poland
Patras, Achaḯa, Greece
Lille, Nord, France
Athens, Attikí, Greece
Tel Aviv, Tell Abīb, Israel
Los Angeles, California, United States
Helsinki, Uusimaa, Finland
Nishinomiya, Hyogo, Japan
Newcastle Upon Tyne, , United Kingdom
Hradec Kralove, , Czechia
Heidelberg, , Germany
Montreal, Quebec, Canada
Santiago De Compostela, , Spain
Bern, Berne, Switzerland
Lublin, Lubelskie, Poland
Lille, Nord, France
Iași, , Romania
Bucuresti, București, Romania
Birmingham, Alabama, United States
Los Angeles, California, United States
Miami, Florida, United States
Atlanta, Georgia, United States
Westwood, Kansas, United States
Baltimore, Maryland, United States
New York, New York, United States
Durham, North Carolina, United States
Philadelphia, Pennsylvania, United States
Salt Lake City, Utah, United States
Madison, Wisconsin, United States
Abb, Ciudad Autónoma De Buenos Aires, Argentina
Buenos Aires, Ciudad Autónoma De Buenos Aires, Argentina
Camperdown, New South Wales, Australia
Brisbane, Queensland, Australia
Adelaide, South Australia, Australia
Clayton, Victoria, Australia
Melbourne, Victoria, Australia
Murdoch, Western Australia, Australia
Linz, Oberösterreich, Austria
Vienna, , Austria
Yvoir, Namur, Belgium
Gent, Oost Vlaanderen, Belgium
Gent, Oost Vlaanderen, Belgium
Belo Horizonte, Minas Gerais, Brazil
São Paulo, Sao Paulo, Brazil
Sao Paulo, São Paulo, Brazil
Calgary, Alberta, Canada
Vancouver, British Columbia, Canada
Halifax, Nova Scotia, Canada
Montreal, Quebec, Canada
Brno, Brno Město, Czechia
Praha 2, , Czechia
Copenhagen, Hovedstaden, Denmark
Aarhus, Midtjylland, Denmark
Odense, Syddanmark, Denmark
Helsinki, Uusimaa, Finland
Creteil, Val De Marne, France
Leipzig, Sachsen, Germany
Heidelberg, , Germany
Wuerzburg, , Germany
Wuerzburg, , Germany
Patras, Achaḯa, Greece
Athens, Attikí, Greece
Chaidari, Attikí, Greece
Budapest, , Hungary
Debrecen, , Hungary
Ramat Gan, Hamerkaz, Israel
Tel Aviv, Tell Abīb, Israel
Jerusalem, Yerushalayim, Israel
Milan, Lombardia, Italy
Rozzano, Milano, Italy
Torino, Piemonte, Italy
Bologna, , Italy
Nagoya, Aichi, Japan
Kashiwa, Chiba, Japan
Nishinomiya, Hyogo, Japan
Kanazawa, Ishikawa, Japan
Fukuoka, , Japan
Kumamoto, , Japan
Okayama, , Japan
Osaka, , Japan
Tokyo, , Japan
Yamagata, , Japan
Seoul, Seoul Teukbyeolsi [Seoul], Korea, Republic Of
Seoul, Seoul Teukbyeolsi [Seoul], Korea, Republic Of
Seoul, Seoul Teukbyeolsi [Seoul], Korea, Republic Of
Seoul, Seoul Teukbyeolsi [Seoul], Korea, Republic Of
Nijmegen, Gelderland, Netherlands
Maastricht, Limburg, Netherlands
Amsterdam, Noord Holland, Netherlands
Groningen, , Netherlands
Utrecht, , Netherlands
Utrecht, , Netherlands
Oslo, , Norway
Gdańsk, Pomorskie, Poland
Katowice, , Poland
Lublin, , Poland
Porto, , Portugal
Bucuresti, București, Romania
Iași, , Romania
Riyadh, , Saudi Arabia
Singapore, Central Singapore, Singapore
Singapore, Central Singapore, Singapore
Santiago De Compostela, A Coruña [La Coruña], Spain
Pamplona, Navarra, Spain
Salamanca, , Spain
Huddinge, , Sweden
St.Gallen, Sankt Gallen, Switzerland
Taipei City, Taipei, Taiwan
Taichung, , Taiwan
Taipei, , Taiwan
Ankara, , Turkey
Cambridge, Cambridgeshire, United Kingdom
Cambridge, England, United Kingdom
London, London, City Of, United Kingdom
Oxford, Oxfordshire, United Kingdom
Manchester, , United Kingdom
Manchester, , United Kingdom
Charlotte, North Carolina, United States
Nova Lima, Minas Gerais, Brazil
München, Bayern, Germany
Nürnberg, Bayern, Germany
Hamburg, , Germany
Hannover, , Germany
łódź, łódzkie, Poland
São Paulo, , Brazil
Hamilton, Ontario, Canada
Pierre Bénite, Rhône, France
Liverpool, New South Wales, Australia
Melbourne, Victoria, Australia
Cleveland, Ohio, United States
Boston, Massachusetts, United States
Milwaukee, Wisconsin, United States
Hradec Kralove, Hradec Králové, Czechia
Genova, , Italy
Udine, , Italy
Lublin, Lubelskie, Poland
Palma, Balears [Baleares], Spain
Badalona, Barcelona [Barcelona], Spain
Granada, , Spain
Roskilde, Sjælland, Denmark
Nantes, Pays De La Loire, France
Chemnitz, Sachsen, Germany
Bern, Berne, Switzerland
Taipei, , Taiwan
Abb, Ciudad Autónoma De Buenos Aires, Argentina
Paris, , France
Munich, Bayern, Germany
Magdeburg, Sachsen Anhalt, Germany
Kiel, Schleswig Holstein, Germany
Berlin, , Germany
Winston Salem, North Carolina, United States
Brussels, Bruxelles Capitale, Région De, Belgium
Nuremberg, , Germany
Lund, , Sweden
Brno, , Czechia
Abb, , Argentina
Abb, , Argentina
Abb, , Argentina
Buenos Aires, , Argentina
Brussels, , Belgium
Sao Paulo, , Brazil
Roskilde, , Denmark
Pierre Bénite, , France
Chaidari, , Greece
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
łódź, , Poland
Santiago De Compostela, , Spain
Palma, , Spain
Badalona, , Spain
Lund, , Sweden
London, , United Kingdom
Edegem, Antwerpen, Belgium
Patients applied
Trial Officials
Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported